CervoMed is trading at $2.37, down 5.58%, with healthcare-sector weakness a possible contributor that does not fully explain the decline.
- Healthcare stocks are down 1.37%, while broad market indexes are only modestly lower.
- CervoMed’s October 12 update reported a decline in a neurodegeneration biomarker in its Phase 2a trial; available coverage does not identify the positive update as the cause of today’s drop.